November 16th, 2026What Pharmacists Should Know About Shifting Peptide PolicyWith patients buying gray-market peptides, HHS’s draft policy aims to reunite prescribers, patients, and pharmacists around these emerging products.Read more
November 16th, 2026Gazyva Approved as First Drug for Primary Membranous NephropathyDespite Gazyva being the first drug accepted to treat this type of nephropathy, it’s already approved for a host of other conditions.Read more
November 16th, 2026FDA Expands Dexmedetomidine for At-Home UseFor patients with schizophrenia or bipolar I or II disorder, dexmedetomidine use will no longer require provider supervision.Read more
November 11th, 2026FDA Approves Asundexian, First FXIa Inhibitor for Stroke PreventionA new option for adults who have experienced stroke will now be available to further reduce future risk.Read more
November 10th, 2026FDA Adds NAION Eye Risk Warning to All GLP-1 LabelsFindings from a meta-analysis of over 125 clinical trials led the agency to require a class-wide label change.Read more
November 9th, 2026FDA Grants Tentative Approval for First Generic LenacapavirGilead’s current lenacapavir patent is what makes Dr Reddy’s Laboratories’ formulation tentative.Read more